USIncomeReport
Saturday, July 2, 2022
  • Economy Indicators
  • Business Insiders
  • Stock Analysis
  • Politics
  • Technology & Science
  • Editor’s Choice
Subscribe
USIncomeReport
  • Economy Indicators
  • Business Insiders
  • Stock Analysis
  • Politics
  • Technology & Science
  • Editor’s Choice
No Result
View All Result
USIncomeReport
No Result
View All Result
Home Economy Indicators

Trump’s experimental treatment from Regeneron puts the company in a ‘very tough situation’ as others request early access, CEO says

October 6, 2020
in Economy Indicators
0
Trump’s experimental treatment from Regeneron puts the company in a ‘very tough situation’ as others request early access, CEO says
152
SHARES
1.9k
VIEWS
Share on FacebookShare on Twitter
  • President Donald Trump’s use of Regeneron Pharmaceutical’s experimental monoclonal antibody treatment puts the company in “a very tough situation,” CEO Leonard Schleifer says.
  • The US President was given an 8 gram injection of Regeneron’s drug over the weekend under the FDA’s “compassionate use” option, as Schleifer said it “just wasn’t practical” to ask a government official to enter a clinical trial.
  • But as infections in the US rise and more than 210,000 Americans have lost their lives from COVID-19, many of those infected and seeking early access like Trump won’t qualify for compassionate use.
  • Visit Business Insider’s homepage for more stories.

President Donald Trump recently took Regeneron Pharmaceutical’s experimental monoclonal antibody treatment, and that has put the company in a difficult situation as it’s starting to receive more requests for early access via the FDA’s “compassionate use” approval process.

Regeneron’s CEO, Dr. Leonard Schleifer, talked generally about the recent development in an interview on Monday while appearing on CNBC’s “Squawk Box” with Meg Tirrell.

“It’s a very tough situation. We have tried to take a principled approach until there is a broader authorization,” Schleifer said during the interview with CNBC. “Basically, if you can get into clinical trials, we’ve tried to encourage people to go into well-controlled, well-monitored, carefully collected data in a clinical trial setting.”

Schleifer added that it “just wasn’t practical” to ask someone such as Trump to enter a clinical trial. Going into a clinical trial has its downsides, Schleifer said, also noting that “you have a 1 in 3 chance of getting placebo.”

Trump was given an 8 gram injection of Regeneron’s drug over the weekend, which is called REGN-COV2 and is a combination of two monoclonal antibodies. The New York-based biotech firm began clinical trials for its experimental treatment on June 11.

Regeneron in the last week said that its drug helped cut down on viral loads and improved symptoms in non-hospitalized COVID-19 patients, with signs it could reduce the chance of someone infected requiring hospitalization.

Schleifer additionally reiterated that the FDA has yet to approve of Regeneron’s drug, and that it was reasonable for someone like Trump to have received it early.

“We want everyone to be potentially able to benefit, we understand we don’t make that decision — this is a decision that the FDA has to make,” he said. “If you’re an essential member of government and you have to conduct the people’s business and the continuity of government and you can’t get to a clinical trial, we’ll take that into account.”

More than 210,000 Americans have lost their lives from COVID-19, according to data from Johns Hopkins University, and new infections continue to spike in some areas of the US.

Schleifer emphasized that the decision to take his company’s experimental monoclonal antibody treatment isn’t something that should be taken lightly, but that he understands people reaching out to inquire about compassionate use access.

“This is all very complicated because it’s real lives at stake,” Schleifer said. “If it’s someone you really care about — yes, we want to give this if we can and we help them, but of course we want to get definitive evidence. So it’s a tough act to balance.”

On Friday, Trump tweeted that he and first lady Melania Trump had tested positive for the coronavirus. They went into isolation, with early news from the White House indicating Trump “was fatigued,” while The New York Times reported that the President “had mild coldlike symptoms.”

Trump was then transported from the White House to the Walter Reed National Military Medical Center in Bethesda, Maryland, where he stayed over the weekend before leaving Monday night.

White House physician Dr. Sean Conley, who’s received backlash for dodging specific questions and not providing enough detailed information in regards to the president’s health, announced on Tuesday that Trump hadn’t reported any symptoms.

“He had a restful first night at home, and today he reports no symptoms,” Conley said. “Overall he continues to do extremely well, I will provide updates as we know more.”

Previous Post

Oracle and Google will face off before the Supreme Court in the most important legal battle in technology. Here’s how the outcome of the decade-long fight could shake up the entire industry. (ORCL, GOOG)

Next Post

Trump senior adviser Stephen Miller tests positive for COVID-19

Next Post
Trump senior adviser Stephen Miller tests positive for COVID-19

Trump senior adviser Stephen Miller tests positive for COVID-19

Start receiving your daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.

Email: 

Your information is secure and your privacy is protected. By opting in you agree to receive emails from us, our partners and affiliates. Remember that you can opt-out any time, we hate spam too!

  • Trending
  • Comments
  • Latest
Exports to EU almost back to pre-Brexit levels

Exports to EU almost back to pre-Brexit levels

May 13, 2021
The Covid-19 Economic Slump Is Closing Down Coal Plants

The Covid-19 Economic Slump Is Closing Down Coal Plants

June 12, 2020
The October bar exam in major jurisdictions like New York and California saw technical glitches for some test-takers — but the exam provider said 98% of users logged in successfully

The October bar exam in major jurisdictions like New York and California saw technical glitches for some test-takers — but the exam provider said 98% of users logged in successfully

October 5, 2020
Japan Airlines will swap ‘ladies and gentlemen’ for gender-neutral terms on its in-flight announcements

Japan Airlines will swap ‘ladies and gentlemen’ for gender-neutral terms on its in-flight announcements

September 30, 2020
Thousands of post Office collection and cash delivery workers to strike on 14 July

Thousands of post Office collection and cash delivery workers to strike on 14 July

0

Post Title

0

Post Title

0
Stocks – Europe Slumps Despite Fed Moves; Autos, Airlines Hit Hard

Stocks – Europe Slumps Despite Fed Moves; Autos, Airlines Hit Hard

0
Thousands of post Office collection and cash delivery workers to strike on 14 July

Thousands of post Office collection and cash delivery workers to strike on 14 July

July 1, 2022
Credit card borrowing falls as consumers feel squeeze

Credit card borrowing falls as consumers feel squeeze

July 1, 2022
Barclays speeds up pay rise to ease staff money worries

Barclays speeds up pay rise to ease staff money worries

July 1, 2022

Post Office scandal victims get £19m interim payout but ‘still in dark over compensation deal’

July 1, 2022

Categories

  • Business Insiders
  • Economy Indicators
  • Editor's Choice
  • Politics
  • Stock Analysis
  • Technology & Science
  • Uncategorized
  • Home
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms & Conditions
  • Email Whitelisting

Disclaimer: USIncomeReport.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

© Copyright 2022, USIncomeReport.com All Rights Reserved

No Result
View All Result
  • Business Insiders
  • Economy Indicators
  • Editor’s Choice
  • Politics
  • Stock Analysis
  • Technology & Science

Disclaimer: USIncomeReport.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

© Copyright 2022, USIncomeReport.com All Rights Reserved